2021 American Academy of Neurology (AAN) Annual Meeting

Virtual 17 April 2021 - 22 April 2021

In utero antiseizure med exposure may not affect early neurodevelopment in children

24 May 2021 by

Exposure to antiseizure medications during pregnancy does not appear to affect neurodevelopmental outcomes in offspring at age 3 years, according to results of the MONEAD* study presented at AAN 2021.

In utero antiseizure med exposure may not affect early neurodevelopment in children

24 May 2021

Stroke rate lower than thought in critically ill COVID-19 patients

21 May 2021 by

Stroke occurred at a relatively low rate of 2.2 percent in critically ill COVID-19 patients in the intensive care unit (ICU) — which is lower than previously thought among COVID-19 patients, according to data from the COVID-19 Critical Care Consortium (CCCC) registry presented at the AAN 2021 Meeting.

Stroke rate lower than thought in critically ill COVID-19 patients

21 May 2021

Once-nightly narcolepsy drug formula may benefit sleepyheads

21 May 2021 by

Use of FT218, an investigational, once-nightly, controlled-release formulation of sodium oxybate (SO), led to clinically significant improvements in sleep parameters in individuals with narcolepsy, according to the secondary endpoint data from the pivotal phase III REST-ON* trial presented at AAN 2021.

Once-nightly narcolepsy drug formula may benefit sleepyheads

21 May 2021

Ubrogepant continues to show benefit for migraine, subgroup analyses show

20 May 2021 by

Subgroup analyses of the ACHIEVE I and II studies presented at AAN 2021 continued to demonstrate favourable outcomes associated with the 50-mg dose of the FDA-approved oral CGRP* receptor antagonist ubrogepant for acute treatment of migraine in adults, particularly among those who were classified as “triptan-insufficient responders”**. Its safety and tolerability were also consistent across various demographic and clinical characteristic subgroups.

Ubrogepant continues to show benefit for migraine, subgroup analyses show

20 May 2021

Neuro features common in children with SARS-CoV-2–related inflammatory syndrome

11 May 2021 by

About 50 percent of children who develop Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 (PIMS-TS) present with neurological features, according to a small study presented at AAN 2021.

Neuro features common in children with SARS-CoV-2–related inflammatory syndrome

11 May 2021

Intranasal zavegepant shows promise for acute migraine treatment

08 May 2021 by

The novel CGRP receptor antagonist zavegepant administered intranasally effectively reduces pain and the most bothersome symptom (MBS) in patients with migraine, shows a study presented at the AAN 2021 Annual Meeting.

Intranasal zavegepant shows promise for acute migraine treatment

08 May 2021

Galcanezumab shows sustained efficacy, CV safety in migraine

05 May 2021 by

Not only does the CGRP* inhibitor galcanezumab show sustained efficacy in migraine patients, long-term treatment does not come with excess cardiovascular (CV) risk, according to studies presented at the AAN 2021 Annual Meeting.

Galcanezumab shows sustained efficacy, CV safety in migraine

05 May 2021

Psychiatric disorders may spur Alzheimer's onset

01 May 2021 by

Individuals with depression or anxiety showed earlier onset of Alzheimer's disease (AD) by 2–3 years compared with those without these psychiatric disorders, according to a study presented at the AAN 2021 Meeting — suggesting that patients with symptoms of depression or anxiety should be monitored for cognitive complaints.

Psychiatric disorders may spur Alzheimer's onset

01 May 2021